...With the seven triptan brands continuing to dominate acute migraine treatment and Ortho- McNeil s Topamax (topiramate) driving sales in the prophylactic market, seven major market revenues increased by 8.1% from 2005 to $3.7 billion in 2006. The launch of pipeline drugs will only periodically offset genericization of GSK s Imitrex (sumatriptan) and Topamax. Further triptan genericization will dictate market dynamics through to 2016. Nevertheless, the largely under served prophylactic market and additional indications such as menstrual migraine will conti nue to present attractive opportunities to both current and future market players. Coverage: Seven major markets (US, Franc e, Germany, Italy, Spain, UK, and Japan) ...

Report Type: Report
Industry(ies): Diversified Services
Free Sample: Click Here to Download

Enter the keyword(s) which you would like to search for within this document and click "Search"

 

 Datamonitor Premium Research Reports
Datamonitor is a premium business information company specializing in industry analysis. Datamonitor's industry research addresses complex strategic issues by providing unbiased expert analysis and in-depth forecasts across the Automotive, Consumer, Energy, Financial Services, Healthcare & Technology sectors.